Bioinformatics Profiling Integrating a Three Immune-related Long Non-coding RNA Signature As a Prognostic Model for Clear Cell Renal Cell Carcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2020 May 22

PMID 32435157

Citations 29

Authors

Yuanbin Jiang

Xin Gou

Zongjie Wei

Jianyu Tan

Haitao Yu

Xiang Zhou

Xinyuan Li

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC) is one of the most common aggressive malignant tumors in urogenital system, and the clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal carcinoma. Immune related long non-coding RNAs (IRlncRs) plentiful in immune cells and immune microenvironment (IME) are potential in evaluating prognosis and assessing the effects of immunotherapy. A completed and meaningful IRlncRs analysis based on abundant ccRCC gene samples from The Cancer Genome Atlas (TCGA) will provide insight in this field.

Methods: Based on the TCGA dataset, we integrated the expression profiles of IRlncRs and overall survival (OS) in the 611 ccRCC patients. The immune score of each sample was calculated based on the expression level of immune-related genes and used to identify the most meaningful IRlncRs. Survival-related IRlncRs (sIRlncRs) was estimated by calculating the algorithm of difference and COX regression analysis in ccRCC patients. Based on the median immune-related risk score (IRRS) developed from the screened sIRlncRs, the high-risk and low-risk components were distinguished. Functional annotation was detected by gene set enrichment analysis (GSEA) and principal component analysis (PCA), and the immune composition and purity of the tumor was evaluated by microenvironment cell population records. The expression levels of three sIRlncRs were verified in various tissues and cell lines.

Results: A total of 39 IRlncRs were collected by Pearson correlation analyses among immune score and the lncRNA expression. A total of 7 sIRlncRs were significantly associated with the clinical outcomes of ccRCC patients. Three sIRlncRs (ATP1A1-AS1, IL10RB-DT and MELTF-AS1) with the most significant prognostic values were enrolled to build the IRRS model in which the OS of in the high-risk group was shorter than that in the low-risk group. The IRRS was identified as an independent prognosis factor and correlated with the OS. The high-risk group and low-risk group illustrated different distributions in PCA and different immune status in GSEA. Besides, we found the more significant expression in certain ccRCC cell lines and tumor tissues of ccRCC patients compared with the HK-2 and adjacent tissues respectively. Additionally, the expression levels of lncR-MELTF-AS1 and IL10RB-DT were remarkably enhanced along the more advanced T-stages, but the lncR-ATP1A1-AS1 showed the inverse gradient.

Conclusion: Our results demonstrate some sIRlncRs with remark clinical relevance show the latent monitoring and prognosis values for ccRCC patients and may provide new insight in immunological researches and treatment strategies of ccRCC patients.

Citing Articles

A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC.

Dai L, Pan D, Jin J, Lv W Aging (Albany NY). 2024; 16(6):5149-5162.

PMID: 38484738 PMC: 11006461. DOI: 10.18632/aging.205633.

The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma.

Zhang Y, Ru N, Xue Z, Gan W, Pan R, Wu Z J Bone Oncol. 2023; 43:100506.

PMID: 37868616 PMC: 10585401. DOI: 10.1016/j.jbo.2023.100506.

Establishment of a new prognostic risk model of GNG7 pathway-related molecules in clear cell renal cell carcinoma based on immunomodulators.

Zheng J, Zhang W, Zhang J BMC Cancer. 2023; 23(1):864.

PMID: 37704946 PMC: 10500784. DOI: 10.1186/s12885-023-11265-8.

Effects of immune inflammation in head and neck squamous cell carcinoma: Tumor microenvironment, drug resistance, and clinical outcomes.

Zhu L, Wang Y, Yuan X, Ma Y, Zhang T, Zhou F Front Genet. 2022; 13:1085700.

PMID: 36579330 PMC: 9790931. DOI: 10.3389/fgene.2022.1085700.

A novel autophagy-related long non-coding RNAs prognostic risk score for clear cell renal cell carcinoma.

Tang F, Tang Z, Lu Z, Cai Y, Lai Y, Mai Y BMC Urol. 2022; 22(1):203.

PMID: 36496360 PMC: 9741795. DOI: 10.1186/s12894-022-01148-8.

References

Qu L, Wang Z, Chen Q, Li Y, He H, Hsieh J . Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6):756-763. DOI: 10.1016/j.eururo.2018.07.032. View

Formisano L, Napolitano F, Rosa R, Damato V, Servetto A, Marciano R . Mechanisms of resistance to mTOR inhibitors. Crit Rev Oncol Hematol. 2020; 147:102886. DOI: 10.1016/j.critrevonc.2020.102886. View

Wei C, Liang Q, Li X, Li H, Liu Y, Huang X . Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. J Cell Biochem. 2019; 120(9):14916-14927. DOI: 10.1002/jcb.28754. View

Song J, Peng J, Zhu C, Bai G, Liu Y, Zhu J . Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma. Cell Physiol Biochem. 2018; 48(6):2549-2562. DOI: 10.1159/000492699. View

Clark D, Dhanasekaran S, Petralia F, Pan J, Song X, Hu Y . Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019; 179(4):964-983.e31. PMC: 7331093. DOI: 10.1016/j.cell.2019.10.007. View

Zhang H, Luo C, Zhang G . LncRNA Regulates Epidermal Growth Factor Receptor and Autophagy to Promote Hepatocellular Carcinoma Metastasis by Interacting with . DNA Cell Biol. 2019; 38(8):857-864. DOI: 10.1089/dna.2019.4770. View

Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L . NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018; 19(10):1112-1125. DOI: 10.1038/s41590-018-0207-y. View

Khadirnaikar S, Kumar P, Pandi S, Malik R, Dhanasekaran S, Shukla S . Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Mol Carcinog. 2018; 58(4):544-553. DOI: 10.1002/mc.22949. View

Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J . An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. Mol Neurobiol. 2017; 55(5):3684-3697. DOI: 10.1007/s12035-017-0572-9. View

10.

Palomero L, Bodnar L, Mateo F, Herranz-Ors C, Espin R, Garcia-Varelo M . EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2020; 12(2). PMC: 7072453. DOI: 10.3390/cancers12020300. View

11.

Hamilton M, Young M, Jang K, Sauer S, Neang V, King A . HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. Cancer Lett. 2019; 472:50-58. PMC: 6992348. DOI: 10.1016/j.canlet.2019.12.022. View

12.

Wang W, Hu W, Wang Y, An Y, Song L, Shang P . Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Mol Cancer. 2020; 19(1):18. PMC: 6988374. DOI: 10.1186/s12943-020-1132-x. View

13.

Devaud C, Westwood J, John L, Flynn J, Paquet-Fifield S, Duong C . Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther. 2013; 22(1):18-27. PMC: 3978809. DOI: 10.1038/mt.2013.219. View

14.

Hahn A, Drake C, Denmeade S, Zakharia Y, Maughan B, Kennedy E . A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist. 2020; 25(2):121-e213. PMC: 7011628. DOI: 10.1634/theoncologist.2019-0599. View

15.

Takagi T, Yoshida K, Wada A, Kondo T, Fukuda H, Ishihara H . Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. Int J Clin Oncol. 2020; 25(5):892-898. DOI: 10.1007/s10147-020-01632-x. View

16.

Figlin R, Tannir N, Uzzo R, Tykodi S, Chen D, Master V . Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020; 26(10):2327-2336. DOI: 10.1158/1078-0432.CCR-19-2427. View

17.

Liu G, Zhao X, Zhou J, Cheng X, Ye Z, Ji Z . LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway. Cell Physiol Biochem. 2018; 48(1):371-384. DOI: 10.1159/000491767. View

18.

Wang T, Lu R, Kapur P, Jaiswal B, Hannan R, Zhang Z . An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discov. 2018; 8(9):1142-1155. PMC: 6125163. DOI: 10.1158/2159-8290.CD-17-1246. View

19.

Pei X, Wang X, Li H . LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018; 118(Pt A):24-30. DOI: 10.1016/j.ijbiomac.2018.06.033. View

20.

Beuselinck B, Verbiest A, Couchy G, Job S, De Reynies A, Meiller C . Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncol. 2017; 57(4):498-508. DOI: 10.1080/0284186X.2017.1388927. View